Related Experiment Video
Updated: Jul 30, 2026
05:42
The Forced Swim Test as a Model of Depressive-like Behavior
Published on: March 2, 2015
Summary
New antidepressant developments, particularly monoamine oxidase inhibitors (MAOIs), are reviewed. Combining an MAOI with amitriptyline lowers but does not eliminate the risk of dangerous blood pressure increases, similar to new reversible MAO-A inhibitors.
Area of Science:
- Pharmacology
- Neuroscience
- Psychiatry
Background:
- Antidepressant medications are crucial for treating mood disorders.
- Monoamine oxidase inhibitors (MAOIs) represent an important class of antidepressants.
- Understanding the safety profile of MAOIs, especially regarding drug interactions, is vital.
Purpose of the Study:
- To review recent pharmacological advancements in antidepressants.
- To specifically examine the role and safety of monoamine oxidase inhibitors (MAOIs).
- To assess the risk of tyramine-induced hypertension when combining MAOIs with amitriptyline.
Main Methods:
- Literature review of pharmacological developments in antidepressants.
- Analysis of studies focusing on monoamine oxidase inhibitors (MAOIs).
- Comparison of cardiovascular risks associated with combined MAOI-amitriptyline therapy versus novel reversible MAO-A inhibitors.
Main Results:
- Combining a monoamine oxidase inhibitor (MAOI) with amitriptyline reduces the risk of a tyramine-induced hypertensive crisis.
- This risk, however, is not entirely eliminated.
- The residual risk is comparable to that observed with newer reversible MAO-A inhibitors, such as CGP 11305A.
Conclusions:
- While combining MAOIs with amitriptyline offers some safety benefits regarding blood pressure, caution is still warranted.
- Newer reversible MAO-A inhibitors present a comparable safety profile for this specific adverse event.
- Further research into the comparative safety and efficacy of different antidepressant classes is essential.
More Related Videos
07:58Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
Published on: February 24, 2023
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Related Concept Videos
01:21G-protein Coupled Receptors
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications